Posted inComunicati
Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE TAIPEI, July 28, 2026 /PRNewswire/ -- Dasher Neuroscience Holdings Inc.…









